摘要
脑卒中具有高发病率、高致残率和高死亡率的特点,是目前导致我国居民死亡的首位病因,其中缺血性卒中占据了脑卒中的87%,但尚缺乏理想的治疗方法。干细胞是一类具有自我更新能力、高度分化潜能的细胞。干细胞移植可打破卒中后梗死区域难以恢复的传统观念。然而,干细胞治疗缺血卒中需要特定的趋化因子诱导其定向迁移至损伤组织部位,基质细胞衍生因子-1α(stromal cell-derived factor-1α,SDF-1α)即是典型代表之一。SDF-1α和其特异性受体CXCR4不仅可以诱导其定性迁移,还能够增加干细胞增殖,促进血管新生。本文就SDF-1α/CXCR4轴在干细胞治疗缺血性脑卒中的作用进行综述,以期为提升干细胞移植治疗缺血性脑卒中的疗效提供理论基础。
Stroke is the leading cause of death in Chinese currently, characterized by high incidence, high morbidity and high mortality, of which ischemic stroke accounted for 87%. However, it still lacks the ideal treatment. Stem cells are a class of cells with self-renewal ability and high differentiation potential. Stem cell transplantation breaks the irreversibility of nerve injury to post-stroke infarct area. However, stem cells also requiring specific chemokines to promote their directional migration to the injured tissue site after transplanted. Stromal cell-derived factor-1α（SDF-1α） is one of the typical chemokines. SDF-1α and its specific receptor CXCR4 can induce its migration, increase its proliferation and promote angiogenesis. In this paper, the role of SDF-1α/CXCR4 axis in the treatment of ischemic stroke in stem cells is reviewed in order to provide a theoretical basis for enhancing the efficacy of stem cell transplantation in the treatment of ischemic stroke.
作者
周欣
楚世峰
万江帆
陈晨
张大永
陈乃宏
ZHOU Xin;CHU Shi-feng;WAN Jiang-fan;CHEN Chen;ZHANG Da-yong;CHEN Nai-hong(China Pharmaceutical University, Nanjing 210009, China;Neuroscience Center, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China)
出处
《药学学报》
CAS
CSCD
北大核心
2018年第7期1054-1059,共6页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81730096)
国家重点实验室开放课题资助项目(GTZK201610)
中国博士后科学基金资助项目(2013M540066)
